Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2026)

Acadia Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $249.6 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $249.6 million; the TTM figure through Mar 2026 stood at $249.6 million (changed N/A YoY), while the FY2025 annual figure was $249.9 million, up 2772.17% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $249.6 million, roughly flat from $249.9 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $249.9 million in Q4 2025, with the low at $1.2 million in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $8.7 million (2024), against an average of $103.2 million.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax increased 27.94% in 2024, then soared 2772.17% in 2025.
• Acadia Pharmaceuticals' Long-Term Deferred Tax stood at $1.2 million in 2022, then surged by 466.67% to $6.8 million in 2023, then rose by 27.94% to $8.7 million in 2024, then jumped by 2772.17% to $249.9 million in 2025, then fell by 0.1% to $249.6 million in 2026.
• Business Quant data shows ACAD's Long-Term Deferred Tax at $249.6 million in Q1 2026, $249.9 million in Q4 2025, and $8.7 million in Q4 2024.